1. not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication) 2. moribund condition (death likely in days) or not expected to survive for \>7 days - due to other and non-covid-19 related conditions 3. patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ecmo) 4. patient within 7 days of participating in other therapeutic clinical trial with angiotensin-converting-enzyme inhibitors (acei), angiotensin receptor blockers (arb) or recombinant ace-2 5. patient not able to take medications by mouth (as capsules or as a powder, mixed in water). 6. disallowed concomitant medication: a. consumption of any herbal products containing 20-hydroxyecdysone and derived from leuzea carthamoides; cyanotis vaga or cyanotis arachnoidea is not allowed (e.g. performance enhancing agents) 7. any known hypersensitivity to any of the ingredients, or excipients of the study medication, bio101 8. in france: * non-affiliation to compulsory french social security scheme (beneficiary or right-holder) * being under tutelage or legal guardianship

1. not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication) 2. moribund condition (death likely in days) or not expected to survive for \>7 days - due to other and non-covid-19 related conditions 3. patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ecmo) 4. patient within 7 days of participating in other therapeutic clinical trial with angiotensin-converting-enzyme inhibitors (acei), angiotensin receptor blockers (arb) or recombinant ace-2 5. patient not able to take medications by mouth (as capsules or as a powder, mixed in water). 6. disallowed concomitant medication: a. consumption of any herbal products containing 20-hydroxyecdysone and derived from leuzea carthamoides; cyanotis vaga or cyanotis arachnoidea is not allowed (e.g. performance enhancing agents) 7. any known hypersensitivity to any of the ingredients, or excipients of the study medication, bio101 8. in france: * non-affiliation to compulsory french social security scheme (beneficiary or right-holder) * being under tutelage or legal guardianship

not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication) moribund condition (death likely in days) or not expected to survive for >7 days - due to other and non-covid-19 related conditions patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ecmo) patient within 7 days of participating in other therapeutic clinical trial with angiotensin-converting-enzyme inhibitors (acei), angiotensin receptor blockers (arb) or recombinant ace-2 patient not able to take medications by mouth (as capsules or as a powder, mixed in water). disallowed concomitant medication: a. consumption of any herbal products containing 20-hydroxyecdysone and derived from leuzea carthamoides; cyanotis vaga or cyanotis arachnoidea is not allowed (e.g. performance enhancing agents) any known hypersensitivity to any of the ingredients, or excipients of the study medication, bio101 in france: non-affiliation to compulsory french social security scheme (beneficiary or right-holder) being under tutelage or legal guardianship

not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication) moribund condition (death likely in days) or not expected to survive for >7 days - due to other and non-covid-19 related conditions patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ecmo) patient within 7 days of participating in other therapeutic clinical trial with angiotensin-converting-enzyme inhibitors (acei), angiotensin receptor blockers (arb) or recombinant ace-2 patient not able to take medications by mouth (as capsules or as a powder, mixed in water). disallowed concomitant medication: a. consumption of any herbal products containing 20-hydroxyecdysone and derived from leuzea carthamoides; cyanotis vaga or cyanotis arachnoidea is not allowed (e.g. performance enhancing agents) any known hypersensitivity to any of the ingredients, or excipients of the study medication, bio101 in france: non-affiliation to compulsory french social security scheme (beneficiary or right-holder) being under tutelage or legal guardianship

1. not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication) 2. moribund condition (death likely in days) or not expected to survive for >7 days - due to other and non-covid-19 related conditions 3. patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ecmo) 4. patient within 7 days of participating in other therapeutic clinical trial with angiotensin-converting-enzyme inhibitors (acei), angiotensin receptor blockers (arb) or recombinant ace-2 5. patient not able to take medications by mouth (as capsules or as a powder, mixed in water). 6. disallowed concomitant medication: a. consumption of any herbal products containing 20-hydroxyecdysone and derived from leuzea carthamoides; cyanotis vaga or cyanotis arachnoidea is not allowed (e.g. performance enhancing agents) 7. any known hypersensitivity to any of the ingredients, or excipients of the study medication, bio101 8. in france: - non-affiliation to compulsory french social security scheme (beneficiary or right-holder) - being under tutelage or legal guardianship

1. not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication) 2. moribund condition (death likely in days) or not expected to survive for >7 days - due to other and non-covid-19 related conditions 3. patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ecmo) 4. patient within 7 days of participating in other therapeutic clinical trial with angiotensin-converting-enzyme inhibitors (acei), angiotensin receptor blockers (arb) or recombinant ace-2 5. patient not able to take medications by mouth (as capsules or as a powder, mixed in water). 6. disallowed concomitant medication: a. consumption of any herbal products containing 20-hydroxyecdysone and derived from leuzea carthamoides; cyanotis vaga or cyanotis arachnoidea is not allowed (e.g. performance enhancing agents) 7. any known hypersensitivity to any of the ingredients, or excipients of the study medication, bio101 8. in france: - non-affiliation to compulsory french social security scheme (beneficiary or right-holder) - being under tutelage or legal guardianship

1. not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication) 2. moribund condition (death likely in days) or not expected to survive for >7 days - due to other and non-covid-19 related conditions 3. patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ecmo), or high flow oxygen 4. patient within 7 days of participating in other therapeutic clinical trial with angiotensin-converting-enzyme inhibitors (acei), angiotensin receptor blockers (arb) or recombinant ace-2 5. patient not able to take medications by mouth (as capsules or as a powder, mixed in water). 6. disallowed concomitant medication: a. consumption of any herbal products containing 20-hydroxyecdysone and derived from leuzea carthamoides; cyanotis vaga or cyanotis arachnoidea is not allowed (e.g. performance enhancing agents) 7. any known hypersensitivity to any of the ingredients, or excipients of the study medication, bio101 8. in france: - non-affiliation to compulsory french social security scheme (beneficiary or right-holder) - being under tutelage or legal guardianship

1. not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication) 2. moribund condition (death likely in days) or not expected to survive for >7 days - due to other and non-covid-19 related conditions 3. patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ecmo), or high flow oxygen 4. patient within 7 days of participating in other therapeutic clinical trial with angiotensin-converting-enzyme inhibitors (acei), angiotensin receptor blockers (arb) or recombinant ace-2 5. patient not able to take medications by mouth (as capsules or as a powder, mixed in water). 6. disallowed concomitant medication: a. consumption of any herbal products containing 20-hydroxyecdysone and derived from leuzea carthamoides; cyanotis vaga or cyanotis arachnoidea is not allowed (e.g. performance enhancing agents) 7. any known hypersensitivity to any of the ingredients, or excipients of the study medication, bio101 8. in france: - non-affiliation to compulsory french social security scheme (beneficiary or right-holder) - being under tutelage or legal guardianship

1. not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication) 2. moribund condition (death likely in days) or not expected to survive for >7 days - due to other and non-covid-19 related conditions 3. patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ecmo), or high flow oxygen 4. patient within 7 days of participating in other therapeutic clinical trial with angiotensin-converting-enzyme inhibitors (acei), angiotensin receptor blockers (arb) or recombinant ace-2 5. patient not able to take medications by mouth (as capsules or as a powder, mixed in water). 6. disallowed concomitant medication: a. consumption of any herbal products containing 20-hydroxyecdysone and derived from leuzea carthamoides; cyanotis vaga or cyanotis arachnoidea is not allowed (e.g. performance enhancing agents) 7. for patients receiving ras pathway modulators (e.g., acei, arb, or renin or aldosterone inhibitors): not on a stable regimen for at least 4 weeks prior to screening or regimen not expected to remain stable for the duration of the study. 8. any known hypersensitivity to any of the ingredients, or excipients of the study medication, bio101 9. renal disease requiring dialysis, or known renal insufficiency (egfr≤30 ml/min/1.73 m2, based on cockroft & gault formula) 10. in france: - non-affiliation to compulsory french social security scheme (beneficiary or right-holder) - being under tutelage or legal guardianship

1. not needing or not willing to remain in a healthcare facility during the entire study medication (i.e. while receiving study medication) 2. moribund condition (death likely in days) or not expected to survive for >7 days - due to other and non-covid-19 related conditions 3. patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ecmo), or high flow oxygen 4. patient within 7 days of participating in other therapeutic clinical trial with angiotensin-converting-enzyme inhibitors (acei), angiotensin receptor blockers (arb) or recombinant ace-2 5. patient not able to take medications by mouth (as capsules or as a powder, mixed in water). 6. disallowed concomitant medication: a. consumption of any herbal products containing 20-hydroxyecdysone and derived from leuzea carthamoides; cyanotis vaga or cyanotis arachnoidea is not allowed (e.g. performance enhancing agents) 7. for patients receiving ras pathway modulators (e.g., acei, arb, or renin or aldosterone inhibitors): not on a stable regimen for at least 4 weeks prior to screening or regimen not expected to remain stable for the duration of the study. 8. any known hypersensitivity to any of the ingredients, or excipients of the study medication, bio101 9. renal disease requiring dialysis, or known renal insufficiency (egfr≤30 ml/min/1.73 m2, based on cockroft & gault formula) 10. in france: - non-affiliation to compulsory french social security scheme (beneficiary or right-holder) - being under tutelage or legal guardianship